AIM ImmunoTech News - August 2026
AIM ImmunoTech's New Cancer Patent Sparks a 34% Rally — But Can a Sub-$10 Million Company Cash In on a $32 Billion Drug Market?
Shares of AIM ImmunoTech surged 34.3% to $0.35 on an otherwise red-tape Monday after the company announced the U.S. Patent and Trademark Office granted it...
🟢 AIM ImmunoTech is trading 34.29% up today after USPTO grants Ampligen-pembrolizumab patent
AIM ImmunoTech is trading 34.29% up now at $0.35 after announcing on August 31, 2026, that the USPTO granted a patent covering Ampligen combined with...
🟢 AIM ImmunoTech is trading 25.66% up today in pre-market
AIM ImmunoTech is trading at $0.32, +25.66%, after rising from the August 28 close of $0.26. • No fresh August 31 company-specific announcement was...
🟢 AIM ImmunoTech is trading 11.69% up today with no clear company-specific catalyst
AIM ImmunoTech is trading 11.69% up at $0.25, with no clear company-specific catalyst identified for August 17, 2026. - Recent second-quarter results, the...
🟢 AIM ImmunoTech is trading 11.6% up in pre-market with no clear company-specific catalyst identified
AIM ImmunoTech is trading 11.6% up in pre-market at $0.25 after closing at $0.22 on August 14, 2026, with no clear company-specific catalyst identified. -...
🔴 AIM ImmunoTech is trading 15% down today with no clear catalyst identified
AIM ImmunoTech is trading 15% down at $0.22 after no clear company-specific catalyst was identified for August 14, 2026. - Recent coverage focused on August...
AIM ImmunoTech Inc Q2 2026 Earnings Preview: What Analysts Expect on August 13, 2026
AIM ImmunoTech is expected to report a Q2 2026 loss of $0.17 per share on minimal revenue of approximately $0.03 million, with its $0.28 stock price currently...